Abstract: The present disclosure relates generally to dosage forms (e.g., oral dosage forms) and pharmaceutical compositions comprising a pharmaceutically active agent comprising pitolisant or a pharmaceutically acceptable salt, solvate, or hydrate thereof, an alkaline agent, a delayed-release coating, and optionally one or more pharmaceutically acceptable excipients; as well as methods of using the dosage forms and pharmaceutical compositions, and methods of making the same.

Abstract: The present disclosure relates to combinations, dosage forms, and pharmaceutical formulations that comprise an active pharmaceutical ingredient, such as pitolisant, and an alkalinizing agent for improving absorption of the active pharmaceutical ingredient.

Abstract: The present disclosure relates generally to a new crystalline form (i.e., polymorph) of pitolisant hydrochloride (Form II), pharmaceutical compositions comprising Form II, dosage forms comprising Form II, and methods of treating a disease or disorder with Form II, or with a pharmaceutical composition or dosage form comprising Form II.

Abstract: The present application concerns novel benzimidazole enantiomeric derivatives, their process of preparation and their therapeutical uses as dual H1 and H4 receptor ligands.

Abstract: The present disclosure relates generally to a new crystalline form (i.e., polymorph) of pitolisant hydrochloride (Form II), pharmaceutical compositions comprising Form II, dosage forms comprising Form II, and methods of treating a disease or disorder with Form II, or with a pharmaceutical composition or dosage form comprising Form II.

Abstract: The present application concerns novel benzimidazole enantiomeric derivatives, their process of preparation and their therapeutical uses as dual H1 and H4 receptor ligands.

Abstract: Novel benzimidazole enantiomeric derivatives, their process of preparation and their therapeutical uses as dual H1 and H4 receptor ligands are disclosed.

Abstract: The present invention concerns new therapeutical uses, including low dosage administration of the highly potent H3-ligand: (3S)-4-{4-[3-(3-methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide.

Abstract: The present invention concerns the tetrahydrate form of the compound: (3S)-4-{4-[3-(3-methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide, dihydrochloride, its process of preparation and therapeutical uses thereof.

Abstract: The present invention concerns new therapeutical uses, including low dosage administration of the highly potent H3-ligand: (3S)-4-{4-[3-(3-methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide.

Abstract: The present invention concerns the tetrahydrate form of the compound: (3S)-4-{4-[3-(3 -methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide, dihydrochloride, its process of preparation and therapeutical uses thereof.

Abstract: Novel benzimidazole enantiomeric derivatives, their process of preparation and their therapeutical uses as dual H1 and H4 receptor ligands are disclosed.

Abstract: The present invention relates to novel compounds acting as agonists at S1P (sphingosine-1-phosphate) receptors, compositions containing these compounds, use of these compounds in medicine and their process of preparation.

Abstract: The present patent application concerns new ligands of the H4-receptor, their process of preparation and their therapeutic use.

Abstract: The present invention concerns novel (aza)benzhydryl ether derivatives which exhibit H4-receptor binding activity. The present invention also concerns their process of preparation and their therapeutical uses.

Abstract: Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, cognitive disorders, motor disorders such as Parkinson's disease, drug addiction, behavioral disorders and inflammatory disorders within the gastrointestinal system. The compounds can also serve as analgesics in the treatment of acute, chronic or recurrent pain.

Abstract: The present patent application concerns new ligands of the H4-receptor, their process of preparation and their therapeutic use.

Abstract: The present patent application concerns new ligands of the H4-receptor, their process of preparation and their therapeutic use.

Abstract: The present invention relates to new compounds of formula (I) possessing agonistic activity at sphingosine-1-phosphate (S1P) receptors, their process of preparation and their use as immunosuppressive agents. The invention is also directed to pharmaceutical compositions containing these compounds and use of these compounds for treatment/prevention of immune mediated diseases and conditions or inflammatory diseases and conditions.

Abstract: The invention relates to compounds of the general formula (I): to the process for preparing them, and to the use thereof as a therapeutic agent.